Serum Pentraxin 3 and hs-CRP Levels in Children with Severe Pulmonary Hypertension
- PMID: 25625020
- PMCID: PMC4299966
- DOI: 10.5152/balkanmedj.2014.13307
Serum Pentraxin 3 and hs-CRP Levels in Children with Severe Pulmonary Hypertension
Abstract
Background: Pulmonary arterial hypertension secondary to untreated left-to-right shunt defects leads to increased pulmonary blood flow, endothelial dysfunction, increased pulmonary vascular resistance, vascular remodelling, neointimal and plexiform lesions. Some recent studies have shown that inflammation has an important role in the pathophysiology of pulmonary arterial hypertension.
Aims: The aim of this study is to evaluate serum pentraxin 3 and high sensitive (hs)-C reactive protein (hs-CRP) levels in children with severe pulmonary arterial hypertension (PAH) secondary to untreated congenital heart defects and evaluate the role of inflammation in pulmonary hypertension.
Study design: Cross sectional study.
Methods: After ethics committee approval and receiving consent from parents, there were 31 children were selected for the study with severe PAH, mostly with a left-to-right shunt, who had been assessed by cardiac catheterisation and were taking specific pulmonary vasodilators. The control group consisted of 39 age and gender matched healthy children. After recording data about all the patients including age, gender, weight, haemodynamic studies and vasodilator testing, a physical examination was done for all subjects. Blood was taken from patients and the control group using peripheral veins to analyse serum Pentraxin 3, N-terminal pro-Brain Natriuretic Peptide (NT-ProBNP) and hs-CRP levels. Serum Pentraxin-3 levels were measured by enzyme linked immunosorbent assay (ELISA) and expressed as ng/mL. Serum hs-CRP levels were measured with an immunonephelometric method and expressed as mg/dL. The serum concentration of NT-proBNP was determined by a chemiluminescent immunumetric assay and expressed as pg/mL.
Results: Serum Pentraxin- 3 levels were determined to be 1.28±2.12 (0.12-11.43) in the PAH group (group 1) and 0.40±0.72 (0.07-3.45) in group 2. There was a statistically significant difference between the two groups (p<0.01). Serum hs-CRP levels were measured as 2.92±2.12 (0.32-14.7) mg/dL in group 1 and 0.35±0.16 (0.07-3.45) mg/dL in group 2. The hs-CRP level was increased in the PAH group to a significant degree (p<0.01).
Conclusion: Our study showed that pentraxin 3 and hs-CRP levels were increased significantly in the PAH group. We consider that inflammation plays an important role in severe pulmonary hypertension and progressive pulmonary arterial hypertension in children with PAH.
Keywords: hs-CRP; inflammation; pentraxin 3; pulmonary arterial hypertension.
Figures
Similar articles
-
Change of hs-CRP, sVCAM-1, NT-proBNP levels in patients with pregnancy-induced hypertension after therapy with magnesium sulfate and nifedipine.Asian Pac J Trop Med. 2013 Nov;6(11):897-901. doi: 10.1016/S1995-7645(13)60160-1. Asian Pac J Trop Med. 2013. PMID: 24083587
-
Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly.Eur J Endocrinol. 2013 Jan 17;168(2):177-84. doi: 10.1530/EJE-12-0753. Print 2013 Feb. Eur J Endocrinol. 2013. PMID: 23132698
-
Pentraxin 3 in neonates with and without diagnosis of pulmonary hypertension.Clin Biochem. 2017 Mar;50(4-5):223-227. doi: 10.1016/j.clinbiochem.2016.11.009. Epub 2016 Nov 10. Clin Biochem. 2017. PMID: 27838407
-
Pulmonary arterial hypertension related to congenital heart disease with a left-to-right shunt: phenotypic spectrum and approach to management.Front Cardiovasc Med. 2024 May 9;11:1360555. doi: 10.3389/fcvm.2024.1360555. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38784170 Free PMC article. Review.
-
The haemodynamic assessment of patients with pulmonary arterial hypertension.Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202004. doi: 10.21542/gcsp.2020.4. Glob Cardiol Sci Pract. 2020. PMID: 33150149 Free PMC article. Review. No abstract available.
Cited by
-
Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension.Open Access Maced J Med Sci. 2019 Aug 14;7(15):2424-2427. doi: 10.3889/oamjms.2019.638. eCollection 2019 Aug 15. Open Access Maced J Med Sci. 2019. PMID: 31666840 Free PMC article.
-
Assessment of Serum suPAR Levels in Patients with Group 1 and Group 4 Pulmonary Hypertension.J Clin Med. 2025 Jul 2;14(13):4671. doi: 10.3390/jcm14134671. J Clin Med. 2025. PMID: 40649045 Free PMC article.
-
Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension.Biomark Insights. 2016 Jun 23;11:85-9. doi: 10.4137/BMI.S38323. eCollection 2016. Biomark Insights. 2016. PMID: 27385910 Free PMC article. Review.
-
Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers.Front Physiol. 2018 May 23;9:609. doi: 10.3389/fphys.2018.00609. eCollection 2018. Front Physiol. 2018. PMID: 29875701 Free PMC article. Review.
References
-
- Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart. 2010;96:1401–6. - PubMed
-
- Fraisse A, Jais X, Schleich JM, di Filippo S, Maragnes P, Beghetti M, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis. 2010;103:66–74. - PubMed
-
- Beghetti M, Tissot C. Pulmonary hypertension in congenital shunts. Rev Esp Cardiol. 2010;63:1179–93. - PubMed
-
- Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular structure in lung biopsy tissue correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation. 1984;69:655–67. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous